Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills Combined Therapy for Qi Deficiency, Phlegm, and Blood Stasis Syndrome in Post-PCI Coronary Heart Disease Patients.

OBJECTIVE

To evaluate the effects of Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills on Qi deficiency, phlegm, and blood stasis syndrome in post-percutaneous coronary intervention (PCI) coronary heart disease (CHD) patients.

METHODS

A retrospective analysis was conducted on 100 post-PCI CHD patients with Qi deficiency, phlegm, and blood stasis syndrome treated from October 2022 to April 2024. Patients were divided into a control group (n=50, receiving standard secondary prevention) and an observation group (n=50, receiving additional Banxia Gualou Xiebai Tang and Qishen Yiqi Dropping Pills). Treatment efficacy, TCM syndrome scores, cardiac function (LVEF, LVEDD, LVESD, CO), blood lipids (TC, TG, HDL-C, LDL-C), hemorheological parameters (PV, Hct, HSBV, LSBV), and adverse events were compared.

RESULTS

① The total effective rate in the observation group (92.0%) was significantly higher than in the control group (76.0%) (P<0.05). ② TCM syndrome scores significantly improved in both groups, with greater improvement in the observation group at 3 and 6 months (P<0.05). ③ Cardiac function: LVEF and CO increased, while LVEDD and LVESD decreased in both groups, with more significant changes in the observation group (P<0.05). ④ Blood lipids: TC, TG, and LDL-C decreased, and HDL-C increased in both groups, with greater changes in the observation group (P<0.05). ⑤ Hemorheology: PV, Hct, HSBV, and LSBV decreased more in the observation group (P<0.05). ⑥ Adverse events: The observation group had a higher incidence of adverse events (22.0% vs 14.0%, P<0.05).

CONCLUSION

Banxia Gualou Xiebai Tang combined with Qishen Yiqi Dropping Pills, alongside standard treatment, significantly improves efficacy, cardiac function, hemorheology, and blood lipids in post-PCI CHD patients without increasing adverse events.